Truscreen Group Ltd. · NZX:TRU
Truscreen — Investor Presentation (March 2017)
13 slides from Truscreen's investor presentation, March 2017
Slide 1: Presentation March 2017
(3) TRUSCREEN Presentation March 2017
Slide 2: Disclaimer
The information in this presentation dated March 2017 is a snapshot and does not contain ALL information necessary to make an investment decision. It DOES NOT PUPORT TO BE A COMPLETE DESCRIPTION OF TRUSCREEN. THIS PRESENTATION IS NOT INVESTMENT ADVICE OR FINANCIAL ADVICE. IN MAKING AN INVESTMENT DEC
Slide 3: New Zealand listed company; key asset
* New Zealand listed company * Key Asset: Opto-electric technology for the detection of cancerous tissue * World's only certified, real time, primary Cervical Cancer screening technology (39 TRUSCREEN’
Slide 4: The World's Only
The World's Only * Real Time * Proven and Certified * Objective * Optical & Electrical * Cervical Cancer « Primary Screening Device (3) TRUSCREEN’
Slide 5: Hardware and Software
Hardware * Entire new device o Wireless Handheld Device o Increased processing capacity o Improved performance via improved design & components o Browser connectivity Software * Significantly improved performance via new algorithim (Z)TRUSCREEN
Slide 6: 1. China
1. CHINA * Secured National KOL support * Confirmed continuation of existing screening programs — mid 2017 * Further screening programs expected — mid 2017 « Approved to supply Chinese military hospitals * Significant marketing and training programs completed countrywide * Regulatory approval in pro
Slide 7: 2. Mexico
2. MEXICO * Regulatory approval granted for TruScreen2 * Government evaluation commenced — mid 2017 decision « KOL, technical & expert evaluation completed * Clinical trial (real world) completed Mexico Real World Performance 2016 TruScreen Pap HPV DNA Sensitivity 78% 36% 56% (3) TRUSCREEN’
Slide 8: 3. Europe
3. EUROPE * Regulatory certification granted (CE) for TruScreen2 ¢ Established European sales and distribution hub from UK ¢ Significantly expanded distribution EU network * Commercial sales commence 2017 (39 TRUSCREEN’
Slide 9: 4. India
4. INDIA ¢« Appointed Indian distribution partner — 7OO employees * Identified large scale government screening opportunity — late 2017-18 * Commenced engagement with Government of India Sales to private sector commence 2017 « World largest screening market of 300M women * Proposing in — country man
Slide 10: Mexico and China outlook
Mexico: o Expect adoption in Government sponsored screening programmes — mid 2017 o Increased sales to private sector in 2017 o Propose expand distribution network into Latin America China: o Expect regulatory approval for TruScreen2 — mid 2017 o Participation in Government screening programs o Incr
Slide 11: Europe and India outlook
Europe: o Initiate sales into new distribution channels o Expand distribution network + 10 countries India: o Initiate sales to private sector o Secure adoption in Government screening programs o Establish in-country manufacturing facilities (39 TRUSCREEN’
Slide 12: Ongoing improvements to clinical performance
Ongoing improvements to clinical performance: * Clinical testing and release of upgraded software — mid 2017 Evaluate adaption of technology to other cancers (39 TRUSCREEN’
Slide 13: Thank You
The world’s only real time primary screening device for cervical cancer Thank You (39 TRUSCREEN’